

Vermillion Appoints Dr. Eric Varma to its Board of Directors

Written by Australian Business

AUSTIN, Texas, Sept. 16, 2013 /PRNewswire/ -- **Vermillion, Inc.** (NASDAQ: [VRML](#)), a multivariate diagnostics company focused on gynecologic cancers and women's health, today announced the appointment of Eric Varma, M.D. to its board of directors.

"As a partner at Oracle Investment Management, Vermillion's largest shareholder, and a physician, Eric brings significant financial and commercial experience in the life sciences to our board of directors," said Thomas McLain, Vermillion's president and CEO. "His expertise will help guide the company as it continues to focus on its novel, high-value diagnostic test, OVA1® and improving the care for women with gynecological cancers."

Dr. Varma is currently a partner at Oracle Investment Management, which is a fundamental research driven investment management company that is exclusively focused on the global health care and bioscience industries. Prior to joining Oracle Investment Management, he worked at Leerink Swann, the Boston Consulting Group, and the Food and Drug Administration. Dr. Varma received his B.A. from the University of California Berkeley, M.D. from the Albert Einstein College of Medicine, and M.B.A. from the MIT Sloan School of Management

About Vermillion Vermillion, Inc. (NASDAQ: [VRML](#)) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared,

Vermillion Appoints Dr. Eric Varma to its Board of Directors

Written by Australian Business

protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com

Forward-Looking Statement Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payers such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov

Investor Relations Contact: Liolios Group, Inc. Ron Both Tel 1-949-574-3860 vrml@liolios.com

Vermillion Appoints Dr. Eric Varma to its Board of Directors

Written by Australian Business

SOURCE Vermillion, Inc.

RELATED LINKS <http://www.vermillion.com>